Zimmer Biomet Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 6, 2016, reports the entry into a Material Definitive Agreement by Zimmer Biomet Holdings, Inc. (Zimmer Biomet). The filing details a proposed acquisition of LDR Holding Corporation (LDR) through a tender offer followed by a merger.
Key Financial Metrics and Transaction Terms
- Offer Price: $37.00 per share in cash, net to the seller.
- Transaction Structure: Zimmer Biomet will cause a subsidiary (Merger Sub) to commence a tender offer for all outstanding LDR shares. Upon completion, Merger Sub will merge with LDR, with LDR surviving as an indirect wholly-owned subsidiary.
- Termination Fee: LDR has agreed to pay Zimmer Biomet $34.2 million if LDR terminates the agreement to accept a superior proposal or if the LDR board withdraws its recommendation.
- Expense Reimbursement: If Zimmer Biomet terminates under certain circumstances, LDR will reimburse up to $11.4 million of Zimmer Biomet's expenses.
- Financial Statements: This filing does not provide revenue, profit, cash flow, or debt metrics for either company. It is a disclosure of the agreement terms only.
Material Changes and Conditions
The transaction is subject to several material conditions, including:
- Tender Threshold: At least a majority of outstanding LDR shares must be validly tendered and not withdrawn.
- Regulatory Approval: Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Board Recommendation: The LDR board has resolved to recommend the offer and agreed not to solicit alternative transactions, subject to customary exceptions.
Outlook, Risks, and Contingencies
- Timeline: The agreement may be terminated if the offer is not consummated by October 6, 2016. This date may be extended to February 6, 2017, specifically to satisfy HSR waiting period conditions.
- Equity Conversion: Outstanding LDR options, restricted stock units, performance stock units, and phantom units will be cancelled and converted into cash at the effective time of the merger.
- Appraisal Rights: Stockholders entitled to demand appraisal rights under Delaware law will not receive the merger consideration automatically but must comply with statutory procedures.
- Future Filings: The tender offer has not yet commenced. Zimmer Biomet and LDR will file a Schedule TO and Schedule 14D-9, respectively, when the offer begins.
Investor Verification Checklist
- Verify the final tender offer materials (Schedule TO) and LDR's recommendation statement (Schedule 14D-9) once filed with the SEC.
- Confirm the status of the HSR antitrust waiting period and any potential extensions to the October 6, 2016 deadline.
- Review the full Agreement and Plan of Merger (Exhibit 2.1) for specific representations, warranties, and covenants not detailed in this summary.
- Monitor for any "superior proposals" that could trigger the $34.2 million termination fee or alter the transaction structure.